Yahoo Web Search

Search results

1. Sorrento Therapeutics, Inc.

   OTC Markets EXMKT: SRNE

   0.0095

   Add to watchlist

   Sign in to add to watchlist

   Sign In

   -0.0005 (-5.00%)

   At close: Thu. Jun 27, 2024 3:17 PM EDT

   Full chart

   • 1D
   • 5D
   • 1M
   • 6M
   • YTD
   • 1Y
   • MAX

   • Open	0.0095
     High	0.0095
     Low	0.0095

   • Mkt Cap	5.51M
     P/E (TTM)	N/A
     Div & Yield	N/A & N/A

   • Prev. Close	0.0100
     52 Wk. Low	0.0001
     52 Wk. High	0.4190

   More about SRNE

   Related stocks

   • VXRT
     Vaxart, Inc.
     VXRT
     0.6660
     -1.45%
   • INO
     Inovio Pharmaceuticals, Inc.
     INO
     7.76
     -0.64%
   • IBIO
     iBio, Inc.
     IBIO
     2.1000
     +1.45%
   • NVAX
     Novavax, Inc.
     NVAX
     12.83
     -2.14%
   • CODX
     Co-Diagnostics, Inc.
     CODX
     1.2700
     -4.51%

   More on Yahoo Finance

2. stocktwits.com › symbol › srneSRNE Sorrento Therapeutics Inc - Stocktwits

   stocktwits.com › symbol › srne

   • Cached

   Track Sorrento Therapeutics Inc (SRNE) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.

3. finance.yahoo.com › quote › SRNESorrento Therapeutics, Inc. (SRNE) Stock Price, News, Quote ...

   finance.yahoo.com › quote › SRNE

   • Cached

   Jun 11, 2024 · Find the latest Sorrento Therapeutics, Inc. (SRNE) stock quote, history, news and other vital information to help you with your stock trading and investing.

4. stocktwits.com › symbol › SRNESRNE Sorrento Therapeutics Inc - Stocktwits

   stocktwits.com › symbol › SRNE

   • Cached

   Find Sorrento Therapeutics Inc (SRNE) news, corporate events, press releases, latest company updates and headlines

5. finance.yahoo.com › quote › SRNESorrento Therapeutics, Inc. (SRNE) - Yahoo Finance

   finance.yahoo.com › quote › SRNE

   • Cached

   Find the latest Sorrento Therapeutics, Inc. (SRNE) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

6. stocktwits.com › symbol › SRNESRNE Sorrento Therapeutics Inc - Stocktwits

   stocktwits.com › symbol › SRNE

   • Cached

   View Sorrento Therapeutics Inc (SRNE) company profile, FAQs, interesting facts, information about industry, sector and employees.

7. seekingalpha.com › symbol › SRNESorrento Therapeutics, Inc. (SRNE) Stock Price, Quote, News ...

   seekingalpha.com › symbol › SRNE

   • Cached

   Jun 21, 2024 · A high-level overview of Sorrento Therapeutics, Inc. (SRNE) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

8. www.google.com › finance › quoteSorrento Therapeutics Inc (SRNE) Stock Price & News - Google

   www.google.com › finance › quote

   • Cached

   Get the latest Sorrento Therapeutics Inc (SRNE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

9. www.zacks.com › stock › quoteSorrento Therapeutics - SRNE - Stock Price Today - Zacks

   www.zacks.com › stock › quote

   • Cached

   Jun 21, 2024 · View Sorrento Therapeutics, Inc SRNE investment & stock information. Get the latest Sorrento Therapeutics, Inc SRNE detailed stock quotes, stock data, Real-Time ECN, charts, stats and...

10. www.bloomberg.com › quote › SRNE:USSRNE: Sorrento Therapeutics Inc Stock Price Quote - OTC US ...

    www.bloomberg.com › quote › SRNE:US

    • Cached

    3 days ago · Stock analysis for Sorrento Therapeutics Inc (SRNE:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

11. www.wsj.com › market-data › quotesSRNE | Sorrento Therapeutics Inc. Stock Price & News - WSJ

    www.wsj.com › market-data › quotes

    • Cached

    Per-Share Earnings, Actuals and Estimates. View the latest Sorrento Therapeutics Inc. (SRNE) stock price, news, historical charts, analyst ratings and financial information from WSJ.